The Filing Desk

Ardelyx

ARDX · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

ARDX · Last close · November 13, 2026
$3.09
Value Ardelyx yourself

Ardelyx's revenue rose 22.1% to $407 million in fiscal 2025. Its operating margin was −10.1%, down from −8.4% a year earlier. Free cash flow was −$44 million. The diluted share count rose 2.5%.

ARDELYX, INC. Latest fiscal year ended December 31, 2025 10-K filed February 19, 2026 · 0001437402-26-000013 Updated
Revenue
$407M
22.1%
Operating margin
−10.1%
1.7 pts
Net income
−$62M
 
Free cash flow
−$44M
 
Return on capital
−36.1%
5.4 pts
Market cap
$772M
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Ardelyx does

Ardelyx is a drug company that sells two medicines in the United States. Both use the same active ingredient, tenapanor, a pill that works in the gut and is barely absorbed into the body. Ardelyx discovered and developed it.

IBSRELA treats adults with irritable bowel syndrome with constipation. Ardelyx says about 13 million Americans have this condition. XPHOZAH lowers phosphorus in the blood of adults with chronic kidney disease who are on dialysis and have not done well on other treatments called phosphate binders. Ardelyx sells both products through its own specialty sales force aimed at stomach and intestine doctors and at kidney doctors.

Ardelyx makes money from sales of these two products. Since January 1, 2025, Medicare has paid for XPHOZAH in a different way, and Ardelyx says this hurt XPHOZAH revenue in 2025. For IBSRELA it names Linzess, Trulance and generic lubiprostone as the main competing products. It has started a late-stage trial of tenapanor in chronic idiopathic constipation, and is developing a next-generation drug of the same type. It has lost money every year since it started in 2007 and has relied on product sales, stock sales, loans and sales of future royalties to fund itself.

Its biggest risks, as it describes them

  • Failing to grow sales of IBSRELA and XPHOZAH enough to produce positive cash flow.
  • Needing more money, and loan terms that limit what it can do and could force repayment.
  • Insurers and Medicare not covering or paying enough for its two products.
  • Competition from other drugs and from companies that may bring products to market faster.
  • Side effects or other problems with its medicines, and product liability lawsuits.
From Ardelyx's annual report on Form 10-K, filed February 19, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Ardelyx lost money in fiscal 2025: a net loss of $62 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments117124184250265
Debt incl. finance leases322750151203
Net debt (negative means net cash)−84−97−134−99−62
Net debt to EBITDA—————
Debt to equity0.4x0.3x0.3x0.9x1.2x
Interest coverage−34.3x−18.8x−12.8x−2.1x−2.0x
Current ratio2.5x2.3x4.9x4.6x4.3x
Quick ratio2.5x1.9x3.9x3.4x2.9x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Ardelyx's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Ardelyx says to expect

  • Full year 2026: IBSRELA revenueFull-year 2026 revenue guidance for IBSRELA reiterated to be between $350 and $370 million.
  • Full year 2026: XPHOZAH revenueFull-year 2026 revenue guidance for XPHOZAH reiterated to be between $110 and $120 million.
  • Full year 2026: operating expensesFull-year 2026 operating expense guidance reiterated to be below $500 million.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 3, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

No officer, director or 10% owner of Ardelyx reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 92 of 92 of 9
Rule of 4066.2%154.3%11.3%
Altman Z''−5.05−2.17−2.34
Accruals ratio9.7%1.6%−4.1%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassPassFail
Cash from operations exceeds net incomeFailFailPass
Debt fell relative to assetsFailFailFail
Current ratio rosePassFailFail
Share count didn't riseFailFailFail
Gross margin roseFailFailPass
Revenue rose relative to assetsPassPassFail
F-score3 of 92 of 92 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Ardelyx side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
ArdelyxFY2522.1%−10.1%−10.8%−36.1%—2
InnovivaFY2514.7%39.8%47.6%17.9%—6Compare
Arcutis BiotherapeuticsFY2591.3%−3.2%−1.7%−16.9%—4Compare
MannKindFY2522.2%11.1%3.9%—3.6x4Compare
Travere TherapeuticsFY25110.5%−12.8%———7Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue—423581052124334407
Revenue growth——−93.8%102.6%43.4%33.4%416.6%138.6%168.1%22.1%
Gross profit—34257948107283368
Research and development94766972659135365272
Operating income−113−65−91−91−91−154−64−63−28−41
Net income−112−64−91−95−94−158−67−66−39−62
Diluted EPS (US$)−2.80−1.36−1.62−1.47−1.05−1.52−0.42−0.30−0.17−0.26
Diluted shares (millions)4047566490104159219235241
Cash flow
Cash from operations−92−65−70−76−81−153−70−90−45−42
Capital expenditure5200020012
Free cash flow−97−68−71−77−82−154−70−90−46−44
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation510910111211143749
Balance sheet at fiscal year end
Cash and short-term investments201134168248186117124184250265
Debt incl. finance leases——525051322750151203
Total assets213158183260202150190298436502
Total liabilities20196873766792131262335
Shareholders' equity1931391161871268398167173167
Margins and ratios
Gross margin—80.0%82.1%88.6%98.1%90.1%92.1%85.7%84.8%90.3%
Operating margin—−155.0%−3,488.6%−1,728.1%−1,199.0%−1,528.6%−122.2%−50.8%−8.4%−10.1%
Net margin—−153.2%−3,502.0%−1,797.8%−1,245.7%−1,566.5%−128.8%−53.1%−11.7%−15.1%
Free cash flow margin—−160.8%−2,707.5%−1,454.4%−1,079.9%−1,529.3%−134.4%−72.4%−13.7%−10.8%
Rule of 40 (growth + FCF margin)——−2,801.3%−1,351.9%−1,036.5%−1,496.0%282.2%66.2%154.3%11.3%
Return on capital————————−41.5%−36.1%
Return on equity−74.4%−38.7%−71.6%−62.8%−60.3%−151.6%−74.3%−49.8%−23.0%−36.2%
Return on assets−68.1%−34.7%−53.5%−42.9%−40.9%−90.0%−39.5%−27.1%−10.7%−13.1%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Ardelyx's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Ardelyx.